+

PE20081225A1 - Formas cristalinas del acido 3-[5-(2-fluorofenil)-[1,2,4]oxadiazol-3-il]-benzoico - Google Patents

Formas cristalinas del acido 3-[5-(2-fluorofenil)-[1,2,4]oxadiazol-3-il]-benzoico

Info

Publication number
PE20081225A1
PE20081225A1 PE2007001290A PE2007001290A PE20081225A1 PE 20081225 A1 PE20081225 A1 PE 20081225A1 PE 2007001290 A PE2007001290 A PE 2007001290A PE 2007001290 A PE2007001290 A PE 2007001290A PE 20081225 A1 PE20081225 A1 PE 20081225A1
Authority
PE
Peru
Prior art keywords
crystalline forms
oxadiazol
fluorophenyl
benzoic acid
refers
Prior art date
Application number
PE2007001290A
Other languages
English (en)
Inventor
Neil G Almstead
Peter Sengwoo Hwang
Young-Choon Moon
Original Assignee
Ptc Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ptc Therapeutics Inc filed Critical Ptc Therapeutics Inc
Publication of PE20081225A1 publication Critical patent/PE20081225A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)

Abstract

SE REFIERE A FORMAS CRISTALINAS DEL ACIDO 3-[5-(2-FLUOROFENIL)-[1,2,4]OXADIAZOL-3-IL]-BENZOICO UTILES EN EL TRATAMIENTO Y PREVENCION DE ENFERMEDADES QUE MEJORAN POR LA MODULACION DE LA TERMINACION PREMATURA DE LA TRADUCCION O LA DESINTEGRACION DE mARN MEDIADO EN SENTIDO CONTRARIO. SE REFIERE TAMBIEN A COMPOSICIONES FARMACEUTICAS Y UN PROCEDIMIENTO DE PREPARACION DE LAS FORMAS CRISTALINAS DONDE UNO DE LOS PATRONES DE DIFRACCION POR RAYOS X DE POLVO COMPRENDE AL MENOS UNA POSICION DE PICO (º2THETA+/-0,2) CUNDO SE MIDE USANDO RADIACION Cu KALFA, SELECCIONADO DEL GRUPO QUE CONSISTE EN 10,10; 11,54; 14,55; 14,88 Y 15,07
PE2007001290A 2006-09-25 2007-09-25 Formas cristalinas del acido 3-[5-(2-fluorofenil)-[1,2,4]oxadiazol-3-il]-benzoico PE20081225A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US84732606P 2006-09-25 2006-09-25

Publications (1)

Publication Number Publication Date
PE20081225A1 true PE20081225A1 (es) 2008-09-04

Family

ID=39123850

Family Applications (3)

Application Number Title Priority Date Filing Date
PE2011001746A PE20120768A1 (es) 2006-09-25 2007-09-25 Formas cristalinas del acido 3-[5-(2-fluorofenil)-[1,2,4\oxadiazol-3-il]-benzoico
PE2007001290A PE20081225A1 (es) 2006-09-25 2007-09-25 Formas cristalinas del acido 3-[5-(2-fluorofenil)-[1,2,4]oxadiazol-3-il]-benzoico
PE2015001242A PE20151445A1 (es) 2006-09-25 2007-09-25 Formas cristalinas del acido 3-[5-(2-fluorofenil)-[1,2,4]oxadiazol-3-il]-benzoico

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2011001746A PE20120768A1 (es) 2006-09-25 2007-09-25 Formas cristalinas del acido 3-[5-(2-fluorofenil)-[1,2,4\oxadiazol-3-il]-benzoico

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2015001242A PE20151445A1 (es) 2006-09-25 2007-09-25 Formas cristalinas del acido 3-[5-(2-fluorofenil)-[1,2,4]oxadiazol-3-il]-benzoico

Country Status (29)

Country Link
US (10) US7863456B2 (es)
EP (2) EP2559689B1 (es)
JP (6) JP5714228B2 (es)
KR (1) KR101430144B1 (es)
CN (3) CN101541770A (es)
AR (2) AR062963A1 (es)
AU (1) AU2007300542B2 (es)
BR (1) BRPI0717107A2 (es)
CA (1) CA2663574C (es)
CL (1) CL2007002743A1 (es)
DK (1) DK2076501T3 (es)
ES (2) ES2563958T3 (es)
HK (1) HK1207070A1 (es)
HU (1) HUE028503T2 (es)
IL (1) IL197717A (es)
LT (1) LTC2076501I2 (es)
MX (2) MX2009003160A (es)
MY (1) MY191209A (es)
NO (1) NO341858B1 (es)
NZ (1) NZ575795A (es)
PE (3) PE20120768A1 (es)
PL (2) PL2559689T3 (es)
PT (1) PT2076501E (es)
SG (2) SG185979A1 (es)
SI (1) SI2076501T1 (es)
TW (2) TWI452038B (es)
UA (1) UA99600C2 (es)
WO (1) WO2008039431A2 (es)
ZA (1) ZA200901949B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3889142B1 (en) 2003-04-11 2022-06-15 PTC Therapeutics, Inc. 1,2,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease
MX2007012206A (es) * 2005-04-08 2007-12-05 Ptc Therapeutics Inc Composiciones de 1,2,4-oxadiazol activo por via oral para terapia de supresion de mutacion interruptora.
NZ596965A (en) * 2006-03-30 2013-06-28 Ptc Therapeutics Inc Methods for the production of functional protein from dna having a nonsense mutation and the treatment of disorders associated therewith
BRPI0717107A2 (pt) * 2006-09-25 2013-10-15 Ptc Therapeutics Inc FORMA DE CRISTAL, FORMA DE DOSAGEM FARMACÊUTICA, E, MÉTODO PARA MODULAR TERMINAÇÃO DE TRANSLAÇÃO PREMATURA OU DETERIORAÇÃO DE mRNA
KR20170100072A (ko) 2006-10-12 2017-09-01 피티씨 테라퓨틱스, 인크. 넌센스 돌연변이 억제 치료를 위한 경구 활성 1,2,4-옥사디아졸의 투여 방법
KR101512548B1 (ko) 2010-03-12 2015-04-15 오메로스 코포레이션 Pde10 억제제 및 관련 조성물 및 방법
WO2014153643A1 (en) * 2013-03-26 2014-10-02 The University Of British Columbia Compositions and methods for use thereof in the treatment of aniridia
EP2981597A1 (en) 2013-04-03 2016-02-10 GFO Oil LLC Methods and systems for generating aldehydes from organic seed oils
EP3363790B1 (en) 2013-09-06 2020-02-19 Aurigene Discovery Technologies Limited 1,2,4-oxadiazole derivatives as immunomodulators
WO2015134711A1 (en) * 2014-03-06 2015-09-11 Ptc Therapeutics, Inc. Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid
NZ630810A (en) 2014-04-28 2016-03-31 Omeros Corp Processes and intermediates for the preparation of a pde10 inhibitor
NZ716462A (en) * 2014-04-28 2017-11-24 Omeros Corp Optically active pde10 inhibitor
KR101703137B1 (ko) 2014-05-30 2017-02-07 선문대학교 산학협력단 당 부가 아미노글리코사이드 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 약학적 조성물
CN105461650B (zh) * 2014-09-12 2018-04-13 杭州普晒医药科技有限公司 一种噁二唑化合物的溶剂化物及其制备方法
PL3267984T3 (pl) 2015-03-10 2022-05-02 Aurigene Discovery Technologies Limited Związki 1,2,4-oksadiazolu i tiadiazolu jako immunomodulatory
WO2016172573A1 (en) 2015-04-24 2016-10-27 Omeros Corporation Pde10 inhibitors and related compositions and methods
EP3368042A4 (en) 2015-10-30 2019-06-26 PTC Therapeutics, Inc. METHOD OF TREATING EPILEPSY
WO2017079678A1 (en) 2015-11-04 2017-05-11 Omeros Corporation Solid state forms of a pde10 inhibitor
CN109152747A (zh) * 2016-04-15 2019-01-04 Uab研究基金会 用于刺激提前终止密码子的通读的方法和化合物
US11207300B2 (en) * 2016-09-13 2021-12-28 Marco Cipolli Method of treatment of Shwachman-diamond syndrome
WO2019061324A1 (en) 2017-09-29 2019-04-04 Curis Inc. CRYSTALLINE FORMS OF IMMUNOMODULATORS
AU2018348350B2 (en) 2017-10-11 2024-05-02 Aurigene Oncology Limited Crystalline forms of 3-substituted 1,2,4-oxadiazole
CN111372584A (zh) 2017-11-03 2020-07-03 奥瑞基尼探索技术有限公司 Tim-3和pd-1途径的双重抑制剂
US11497735B2 (en) 2017-11-06 2022-11-15 Aurigene Discovery Technologies Limited Conjoint therapies for immunomodulation
CA3135641A1 (en) 2019-04-10 2020-10-15 Ptc Therapeutics, Inc. Method for treating nonsense mutation mediated duchenne muscular dystrophy in pediatric patients
JP7339900B2 (ja) * 2020-02-26 2023-09-06 新 井上 視野異常診断方法、視野異常診断装置
KR102665711B1 (ko) * 2021-12-21 2024-05-14 재단법인 아산사회복지재단 Ras 활성도를 이용한 신경섬유종증 치료제에 대한 감수성 예측용 바이오마커 조성물 및 Ras 활성 억제제를 포함하는 신경섬유종증 예방 또는 치료용 약학적 조성물
CN118178408A (zh) * 2024-03-22 2024-06-14 核工业总医院 Ptc124在制备治疗血小板无力症的药物中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW264475B (es) 1991-09-20 1995-12-01 Takeda Pharm Industry Co Ltd
US6660753B2 (en) 1999-08-19 2003-12-09 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
US7041685B2 (en) 2001-06-08 2006-05-09 Cytovia, Inc. Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof
MY151199A (en) 2001-11-02 2014-04-30 Rigel Pharmaceuticals Inc Substituted diphenyl heterocycles useful for treating hcv infection
AU2003247610A1 (en) * 2002-06-21 2004-01-06 Ptc Therapeutics, Inc. METHODS FOR IDENTIFYING SMALL MOLECULES THAT MODULATE PREMATURE TRANSLATION TERMINATION AND NONSENSE MEDIATED mRNA DECAY
US6889231B1 (en) * 2002-08-01 2005-05-03 Oracle International Corporation Asynchronous information sharing system
CN1691944A (zh) 2002-08-09 2005-11-02 阿斯利康(瑞典)有限公司 作为代谢型谷氨酸受体－5调节剂的噁二唑
GB0303503D0 (en) 2003-02-14 2003-03-19 Novartis Ag Organic compounds
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
EP3889142B1 (en) 2003-04-11 2022-06-15 PTC Therapeutics, Inc. 1,2,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease
US20050075375A1 (en) 2003-05-14 2005-04-07 Anadys Pharmaceuticals, Inc. Heterocyclic compounds for treating hepatitis C virus
US7902235B2 (en) * 2004-10-13 2011-03-08 Ptc Therapeutics, Inc. Compounds for nonsense suppression, and methods for their use
WO2006063215A2 (en) * 2004-12-08 2006-06-15 Biomarin Pharmaceutical Inc. Methods and compositions for the treatment of pulmonary hypertension of the newborn
MX2007012206A (es) * 2005-04-08 2007-12-05 Ptc Therapeutics Inc Composiciones de 1,2,4-oxadiazol activo por via oral para terapia de supresion de mutacion interruptora.
MY148598A (en) 2006-09-08 2013-05-15 Ptc Therapeutics Inc Processes for the preparation of 1,2,4-oxadiazole benzoic acids
BRPI0717107A2 (pt) * 2006-09-25 2013-10-15 Ptc Therapeutics Inc FORMA DE CRISTAL, FORMA DE DOSAGEM FARMACÊUTICA, E, MÉTODO PARA MODULAR TERMINAÇÃO DE TRANSLAÇÃO PREMATURA OU DETERIORAÇÃO DE mRNA
WO2015134711A1 (en) * 2014-03-06 2015-09-11 Ptc Therapeutics, Inc. Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid

Also Published As

Publication number Publication date
IL197717A (en) 2015-06-30
EP2559689B1 (en) 2017-11-29
WO2008039431A3 (en) 2008-05-08
JP2023078271A (ja) 2023-06-06
WO2008039431B1 (en) 2008-07-10
US10028939B2 (en) 2018-07-24
US10959988B2 (en) 2021-03-30
JP5714228B2 (ja) 2015-05-07
EP2076501B1 (en) 2015-12-02
NZ575795A (en) 2012-03-30
ZA200901949B (en) 2010-07-28
PL2559689T3 (pl) 2018-04-30
US8748625B2 (en) 2014-06-10
JP6495375B2 (ja) 2019-04-03
MX344418B (es) 2016-12-15
US10300047B2 (en) 2019-05-28
US20220023268A1 (en) 2022-01-27
TW201420578A (zh) 2014-06-01
US20130158081A1 (en) 2013-06-20
CN102382075B (zh) 2015-10-28
ES2563958T3 (es) 2016-03-16
RU2474577C2 (ru) 2013-02-10
CN104341371A (zh) 2015-02-11
NO341858B1 (no) 2018-02-12
US20140235679A1 (en) 2014-08-21
US20110040100A1 (en) 2011-02-17
SI2076501T1 (sl) 2016-05-31
EP2076501B8 (en) 2019-11-13
JP6407733B2 (ja) 2018-10-17
EP2559689A1 (en) 2013-02-20
JP2019104752A (ja) 2019-06-27
NO20091488L (no) 2009-06-17
AR109300A2 (es) 2018-11-14
TW200823181A (en) 2008-06-01
US20080171377A1 (en) 2008-07-17
UA99600C2 (en) 2012-09-10
SG185979A1 (en) 2012-12-28
TWI496775B (zh) 2015-08-21
DK2076501T3 (da) 2016-02-29
KR101430144B1 (ko) 2014-08-13
JP2010504340A (ja) 2010-02-12
WO2008039431A2 (en) 2008-04-03
LTC2076501I2 (lt) 2017-10-10
RU2009115649A (ru) 2010-11-10
JP7245868B2 (ja) 2023-03-24
US7863456B2 (en) 2011-01-04
MX2009003160A (es) 2009-04-06
JP2021130697A (ja) 2021-09-09
CN102382075A (zh) 2012-03-21
US20210330647A1 (en) 2021-10-28
IL197717A0 (en) 2009-12-24
CA2663574A1 (en) 2008-04-03
CA2663574C (en) 2015-11-24
US20180296538A1 (en) 2018-10-18
EP2076501A2 (en) 2009-07-08
US20190231754A1 (en) 2019-08-01
BRPI0717107A2 (pt) 2013-10-15
AU2007300542A1 (en) 2008-04-03
US9309206B2 (en) 2016-04-12
PT2076501E (pt) 2016-03-31
JP2015110607A (ja) 2015-06-18
US20160193189A1 (en) 2016-07-07
HK1207070A1 (en) 2016-01-22
PE20151445A1 (es) 2015-09-28
US20200330440A1 (en) 2020-10-22
AU2007300542B2 (en) 2012-05-17
SG10201609581TA (en) 2016-12-29
ES2655338T3 (es) 2018-02-19
TWI452038B (zh) 2014-09-11
MY191209A (en) 2022-06-08
US8394966B2 (en) 2013-03-12
CN101541770A (zh) 2009-09-23
PL2076501T3 (pl) 2016-06-30
AR062963A1 (es) 2008-12-17
JP2017160253A (ja) 2017-09-14
KR20090057457A (ko) 2009-06-05
HUE028503T2 (en) 2016-12-28
PE20120768A1 (es) 2012-06-27
CL2007002743A1 (es) 2008-07-11

Similar Documents

Publication Publication Date Title
PE20081225A1 (es) Formas cristalinas del acido 3-[5-(2-fluorofenil)-[1,2,4]oxadiazol-3-il]-benzoico
EA201200794A1 (ru) Триазолопиридины
CY1119730T1 (el) Παραγωγα καρβοξυλικου οξεος πυρρολιδινης ως αγωνιστες του συζευγμενου με πρωτεϊνή-g υποδοχεα 43 (gpr43), φαρμακευτικη συνθεση και μεθοδοι για χρηση στην αντιμετωπιση μεταβολικων διαταραχων
UY29648A1 (es) Derivados de piridopirimidina, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones
BR112012002134B8 (pt) compostos inibidores de apaf-1
WO2008079291A3 (en) Substituted heterocycles and methods of use
DOP2011000218A (es) Derivados de sulfonamida
MX2011012122A (es) Derivados de tiofeno.
ECSP11011253A (es) Composición farmacéutica sólida que comprende amlodipina y losartan
UY32072A (es) Tienopirimidinas para composiciones farmacéuticas
GT200600086A (es) Forma cristalina de gamma-d del clorhidrato de ivabradina, su procedimiento de preparación y composiciones farmacéuticas que la contienen
MX2009006543A (es) Compuestos heterociclicos y su uso en el tratamiento de la inflamacion, angiogenesis y cancer.
GT200800242A (es) Derivados biciclicos como inhibidores de cetp
UA98373C2 (ru) Конденсированные гетероциклические производные и их применение как c-met ингибиторов
DE602006013940D1 (de) Oral zerfallende zusammensetzung von olanzapin oder donepezil
NI200800294A (es) Nueva forma cristalina vi de la agomelatina, su procedimiento de preparacion y las composiciones farmacéuticas que la contienen.
EA200971115A1 (ru) Новые ингибиторы обратной транскриптазы вич
UA110013C2 (uk) Застосування композиції для лікування шарко-марі-тута і пов'язаних з нею розладів
CL2009000381A1 (es) Compuestos derivados de tiazol o tiazol-5-carboxamida, inhibidores de la actividad estearoil-coa-desaturasa humana (scd); composicion farmaceutica; y uso para el tratamiento de un trastorno o enfermedad mediada por las enzimas de scd, tal como diabetes, obesidad, enfermedad cardiovascular, lipidos elevados, entre otras.
UY30863A1 (es) Derivados de piridopirimidina, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
GEP20135806B (en) Lactams as beta secretase inhibitors
EA201270410A1 (ru) Производное инденона и содержащая его фармацевтическая композиция
ATE372995T1 (de) Benzo(b)(1,4)dioxepinderivate
EP2796450A4 (en) 6-AMINOPYRIDIN-3-OL DERIVATIVES OR PHARMACEUTICAL SALTS AND / OR PHARMACEUTICAL COMPOSITION THEREOF AS ACTIVE AGENTS FOR THE PREVENTION OR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES
NZ597866A (en) Therapeutic lactams

Legal Events

Date Code Title Description
FC Refusal
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载